Corporate Communications: Drew McGray
949.309.3525

ACAM Supports NIH Decision to Suspend TACT Trial

September 3, 2008, Laguna Hills, Calif. -- The American College for Advancement in Medicine, ACAM today announced its support for the National Institute for Health's (NIH) decision to suspend patient accrual of  the Trial to Assess Chelation Therapy (TACT) Trial until allegations of impropriety can be proven false.  ACAM believes that the TACT trial represents a important milestone in assessing the role of chelation therapy in modern healthcare and respects the decision of the NIH.

ACAM continue to work with Dr Tony Lamas to answer the unfounded allegations of impropriety.

"We believe that the Office of Human Research Protection (OHRP) will find that the allegations are of a political nature. To serve the best interests of participants enrolled in the TACT trial and all patients and their physicians who seek answers about chelation therapy, we call for a swift end to the moratorium and resumption of the trial," said Jeanne Drisko, MD, President of ACAM.

For the most current information about the TACT trial visit: http://nccam.nih.gov/chelation/

About ACAM:
The American College for Advancement in Medicine (ACAM) is a not-for-profit association dedicated to educating physicians and other health care professionals on the latest findings and emerging procedures in complementary, alternative and integrative (CAIM) medicine. ACAM is the voice of integrative medicine; our goals are to improve physician skills, knowledge and diagnostic procedures as they relate to complementary and alternative medicine; to support integrative medicine research; and to develop awareness of alternative methods of medical treatment. ACAM enables members of the public to connect with physicians who take an integrative approach to patient care and empowers people with information about integrative medicine treatment options.